Dashboard
Manage Tickers

INCY INCYTE CORP

Nasdaq incyte.com


$ 86.28 $ -1.40 (-1.6 %)    

Monday, 20-Oct-2025 17:02:38 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 612.11 $ 7.61 (1.26 %)
DIA $ 467.12 $ 5.24 (1.13 %)
SPY $ 671.75 $ 6.91 (1.04 %)
TLT $ 91.68 $ 0.35 (0.38 %)
GLD $ 401.36 $ 14.16 (3.64 %)
$ 86.17
$ 87.45
$ 82.00 x 5
$ 89.03 x 400
-- - --
$ 53.56 - $ 92.86
2,100,676
na
16.83B
$ 0.47
$ 19.32
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-29-2025 06-30-2025 10-Q
2 04-29-2025 03-31-2025 10-Q
3 02-10-2025 12-31-2024 10-K
4 10-29-2024 09-30-2024 10-Q
5 07-30-2024 06-30-2024 10-Q
6 04-30-2024 03-31-2024 10-Q
7 02-13-2024 12-31-2023 10-K
8 10-31-2023 09-30-2023 10-Q
9 08-01-2023 06-30-2023 10-Q
10 05-02-2023 03-31-2023 10-Q
11 02-07-2023 12-31-2022 10-K
12 11-01-2022 09-30-2022 10-Q
13 08-02-2022 06-30-2022 10-Q
14 05-03-2022 03-31-2022 10-Q
15 02-08-2022 12-31-2021 10-K
16 11-02-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 05-04-2021 03-31-2021 10-Q
19 02-09-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-04-2020 06-30-2020 10-Q
22 05-05-2020 03-31-2020 10-Q
23 02-13-2020 12-31-2019 10-K
24 10-30-2019 09-30-2019 10-Q
25 07-30-2019 06-30-2019 10-Q
26 04-30-2019 03-31-2019 10-Q
27 02-14-2019 12-31-2018 10-K
28 10-30-2018 09-30-2018 10-Q
29 07-31-2018 06-30-2018 10-Q
30 05-01-2018 03-31-2018 10-Q
31 02-15-2018 12-31-2017 10-K
32 10-31-2017 09-30-2017 10-Q
33 08-01-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 02-14-2017 12-31-2016 10-K
36 11-01-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 02-12-2016 12-31-2015 10-K
40 11-03-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

reported-sunday-incytes-inca33890-demonstrates-durable-responses-in-mss-colorectal-cancer-company-to-advance-program-toward-2026-registration
Reported Sunday, Incyte's INCA33890 Demons...
10/20/2025 07:06:34

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment i...

reported-sunday-incyte-highlights-early-clinical-results-for-inca33890-and-incb161734-showing-potential-in-advanced-solid-tumors
Reported Sunday, Incyte Highlights Early C...
10/13/2025 06:36:49

what-14-analyst-ratings-have-to-say-about-incyte
What 14 Analyst Ratings Have To Say About ...
10/09/2025 18:00:26

incyte-appoints-thomas-tray-as-principal-financial-officer
Incyte Appoints Thomas Tray As Principal F...
10/03/2025 20:04:16

On September 30, 2025, the Board of Directors of Incyte Corporation (the "Company") appointed Thomas Tray, the Company&...

reported-sunday-ruxolitinib-cream-achieves-78-easi-75-response-in-china-phase-3-atopic-dermatitis-trial-conducted-by-china-medical-system
Reported Sunday, Ruxolitinib Cream Achieve...
09/29/2025 06:49:39

rbc-capital-maintains-sector-perform-on-incyte-raises-price-target-to-81
RBC Capital Maintains Sector Perform on In...
09/24/2025 13:59:07

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $72...

jim-cramer-spotlights-these-undervalued-sp-500-stocks-with-growth-potential-amid-skyrocketing-market
Jim Cramer Spotlights These Undervalued S&...
09/23/2025 09:14:41

In a recent episode of "Mad Money," Jim Cramer identified several stocks in the S&P 500 that he believes are underv...

stifel-maintains-buy-on-incyte-raises-price-target-to-115
Stifel Maintains Buy on Incyte, Raises Pri...
09/22/2025 17:05:58

Stifel analyst Stephen Willey maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $110 to $115.

incyte-stock-a-deep-dive-into-analyst-perspectives-11-ratings
Incyte Stock: A Deep Dive Into Analyst Per...
09/19/2025 19:02:00

guggenheim-reiterates-neutral-on-incyteto-neutral
Guggenheim Reiterates Neutral on Incyteto ...
09/19/2025 12:43:54

Guggenheim analyst Michael Schmidt reiterates Incyte (NASDAQ:INCY) from Neutral to Neutral.

fda-expands-incytes-opzelura-approval-to-treat-atopic-dermatitis-in-children
FDA Expands Incyte's Opzelura Approval To ...
09/19/2025 12:38:42

FDA approves Incyte's Opzelura cream for children aged two and older with atopic dermatitis, expanding its use beyond teens...

incyte-earns-fda-approval-for-its-opzelura-cream-for-children-ages-2-11-with-atopic-dermatitis
Incyte Earns FDA Approval For Its Opzelura...
09/18/2025 20:24:41

Opzelura is the first topical JAK inhibitor approved in the U.S. for pediatric atopic dermatitis (AD)Phase 3 data supporting th...

incyte-presents-new-24-week-stop-hs-phase-3-data-demonstrating-statistically-significant-improvements-with-povorcitinib-in-hs-patients
Incyte Presents New 24-Week STOP-HS Phase ...
09/17/2025 06:15:22

incyte-to-present-new-data-from-dermatology-portfolio-at-eadv-2025-congress
Incyte To Present New Data From Dermatolog...
09/10/2025 11:33:05

- 24-week data from the Phase 3 STOP-HS clinical trial program of povorcitinib in patients with hidradenitis suppurativa (HS) s...

b-of-a-securities-maintains-buy-on-incyte-raises-price-target-to-104
B of A Securities Maintains Buy on Incyte,...
09/04/2025 18:01:09

B of A Securities analyst Tazeen Ahmad maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $90 to $104.

sp-500-losers-22-stocks-with-negative-returns-over-past-10-years-and-this-ones-getting-the-boot
S&P 500 Losers: 22 Stocks With Negative Re...
08/26/2025 17:02:05

The S&P 500 Index is up over 200% over the past decade, but 22 stocks have declined during that period, and one is set to b...

13-analysts-have-this-to-say-about-incyte
13 Analysts Have This To Say About Incyte
08/22/2025 18:02:24

jp-morgan-maintains-neutral-on-incyte-raises-price-target-to-73
JP Morgan Maintains Neutral on Incyte, Rai...
08/22/2025 14:17:52

JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $67 to $73.

beyond-the-numbers-12-analysts-discuss-incyte-stock
Beyond The Numbers: 12 Analysts Discuss In...
08/06/2025 18:03:05

wells-fargo-upgrades-incyte-to-overweight-raises-price-target-to-89
Wells Fargo Upgrades Incyte to Overweight,...
08/06/2025 12:22:23

Wells Fargo analyst Derek Archila upgrades Incyte (NASDAQ:INCY) from Equal-Weight to Overweight and raises the price target ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION